Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 8th International Workshop on Acute Leukemias (iwAL) took place on 18-20 September, 2026, in Cambridge, MA, and brought together the world’s leading clinicians and researchers in acute leukemias to discuss the latest updates in the field. The iwAL 2026 Workshop was supported by Daiichi-Sankyo, AbbVie, Astellas, Genentech, Kura Oncology, Sumitomo Pharma, Syndax, Invivoscribe, and Johnson & Johnson. Supporters have no influence over the production of content.
iwAL 2026
The 8th International Workshop on Acute Leukemias
18–20 September 2026 | Cambridge, MA
The 8th International Workshop on Acute Leukemias (iwAL) took place on 18-20 September, 2026, in Cambridge, MA, and brought together the world’s leading clinicians and researchers in acute leukemias to discuss the latest updates in the field. The iwAL 2026 Workshop was supported by Daiichi-Sankyo, AbbVie, Astellas, Genentech, Kura Oncology, Sumitomo Pharma, Syndax, Invivoscribe, and Johnson & Johnson. Supporters have no influence over the production of content.
Explore roundtable discussions and interviews
View all videos
Understanding the biology and pathogenesis of DS
Clinical presentations and treatment of DS
Translational and lab developments and applications in AML
New science implications for AML
New frontiers in MRD for AML: Regulatory perspective and clinical practice
Updates on established therapies in AML
Immunotherapies in AML
Targeting FLT3-mutant AML
Transplantation in AML
Clonal hematopoiesis, BPDCN & CMML
Menin inhibitors in AML
TP53-mutated AML
Novel targets and advances in our understanding of AML
Novel combinations and treatments in AML
Understanding the biology and pathogenesis of DS
Corticosteroids and unravelling the spectrum of differentiation syndromes in AML
Justin Watts University of Miami, Miami , FL, United States
Coming soon
Pathogenesis of DS
Stéphane de Botton Gustave Roussy, Paris, France
Initial recognition of differentiation syndrome with ATRA in APL
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Clinical presentations and treatment of DS
Patterns of differentiation syndrome in menin-inhibitor treated patient
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Ziftomenib-induced DS: lessons learned
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Coming soon
Menin inhibitor syndrome: Treatment algorithm and future directions
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
Coming soon
Translational and lab developments and applications in AML
Understanding the biology and therapeutic potential of RAS in frontline AML and CMML
Sandra Misale Johns Hopkins Medicine, Baltimore, MD, United States
New science implications for AML
Role of Pi3K gamma inhibition in AML
Andrew Lane Dana-Farber Cancer Institute, Boston, MA, United States
STAT3 inhibition in MDS and AML
Aditi Shastri Albert Einstein College of Medicine, New York City, NY, United States
New frontiers in MRD for AML: Regulatory perspective and clinical practice
Cell-free DNA determinants of AML MRD
Tian Yi Zhang Stanford Cancer Institute , Stanford , CA, United States
MRD as a clinical endpoint in clinical trials: Updates from recent datasets
Gege Gui Virginia Tech FBRI Cancer Center, Washington, D.C., United States
MRD in AML: FDA’s regulatory perspective
Cara Rabik FDA, Silver Spring, MD, United States
Updates on established therapies in AML
Optimal dose of VEN in AML therapy (OPTI-AML)
Uma Borate Ohio State University, Columbus, OH, United States
Incorporating VEN to IC based induction – current status
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Optimal dose, duration and de-escalation of venetoclax
Stéphane de Botton Gustave Roussy, Paris, France
Immunotherapies in AML
AVC-201: A CAR T using a switchable module in AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
SENTI-202: A logically gated off-the-shelf cell therapy for AML
Stephen Strickland SCRI at TriStar Bone Marrow Transplant, Nashville, TN, United States
Novel targets for T-cell engagers in relapsed/refractory AML
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Coming soon
Pivekimab sunirine
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Targeting FLT3-mutant AML
Frontline approaches for fit patients with FLT3-mutant AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Does the choice of FLT3 inhibitor really matter?
Alexander Perl University of Pennsylvania, Philadelphia, PA, United States
Coming soon
Managing FLT3-ITD+ AML in remission
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Resistance mechanisms
Catherine Smith University of California, San Francisco, San Francisco, CA, United States
Coming soon
Transplantation in AML
Strategies to reduce relapse risk post-transplant
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Coming soon
Precision-engineered T-cell immunotherapy for alloHSCT
Samer Srour University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Clonal hematopoiesis, BPDCN & CMML
Potential for early intervention in CHIP and CCUS: Updates and ongoing trials
Uma Borate Ohio State University, Columbus, OH, United States
Coming soon
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): New approaches
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Molecular biology and clinical outcomes of blast transformed CMML
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Coming soon
Menin inhibitors in AML
Second-generation menin inhibitors, MEN1 mutations, and resistance
Justin Watts University of Miami, Miami , FL, United States
Coming soon
Menin inhibition for MRD
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Breaking resistance: combinations and next-generation approaches in menin-driven AML
Emma Searle The Christie NHS Foundation Trust, Manchester, United Kingdom
Coming soon
Paradigm shift with menin inhibitor triplets: Moving beyond unfit/older AML
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
TP53-mutated AML
Biological insights and better understanding TP53m AML
Jayastu Senapati MD Anderson Cancer Center, Houston, TX, United States
Coming soon
New approaches to target TP53m AML
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Coming soon
TP53-mutated AML and transplant
Pramila Krishnamurthy King's College Hospital, London, United Kingdom
Coming soon
Current challenges and future strategies for TP53-mutated AML and MDS
Maximilian Stahl Yale Cancer Center, New Haven, CT, United States
Coming soon
TP53 Potpourri
Gabriel Mannis Stanford University School of Medicine, Stanford, CA, United States
Coming soon
Novel targets and advances in our understanding of AML
Beyond genomics: Soluble proteomics in AML
Hussein Abbas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Molecular complexity in AML
Ann-Kathrin Eisfeld The Ohio State University, Columbus, OH, United States
Coming soon
Novel targets in AML and their implications for the practicing hematopathologist
Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Novel combinations and treatments in AML
Combinations with AZA/VEN
Thomas Cluzeau Central University Hospital of Nice, France
Coming soon
Intensive or non-intensive induction (PARADIGM)
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Coming soon
How and when to use oral decitabine in AML
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Coming soon
Combination strategies
Himachandana Atluri The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Diamond-01 trial (MEN1703 [SEL24])
Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Coming soon
Novel combinations in IDH1 mutant AML
Pinkal Desai Weill Cornell Medical College, New York, NY, United States
Coming soon
The iwAL 2026 meeting was supported by:
